PROCEPT BioRobotics (PRCT) News Today

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares remain under pressure following a combination of weaker-than-expected profitability, concerns about product demand and multiple securities-fraud lawsuits. The stock is trading near its 12-month low and below its 50-day and 200-day moving averages, while trading volume has been elevated.

• Positive Sentiment: Second-quarter revenue increased 19.3% year over year to $94.5 million, exceeding analysts’ $92.77 million consensus estimate. The company’s full-year 2026 revenue outlook of $390 million to $410 million is broadly in line with the $397.2 million consensus, suggesting continued growth in its urology-focused surgical robotics business. PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Several law firms announced or promoted securities class-action claims covering investors who purchased PRCT shares from February 28, 2024, through February 25, 2026. The lead-plaintiff deadline is generally September 22, 2026, although one Kaplan Fox notice cites September 28. These announcements largely repeat the same lawsuit rather than representing separate legal actions. Kaplan Fox Securities Class Action Notice
• Negative Sentiment: PROCEPT reported a second-quarter loss of $0.47 per share, slightly worse than the $0.46 consensus loss and wider than the $0.35 loss in the prior-year period. Persistent losses, including a negative net margin, are weighing on investor confidence despite revenue growth. PROCEPT Q2 Loss Report
• Negative Sentiment: The lawsuits allege that PROCEPT used late-quarter discounts and bulk handpiece orders to inflate demand and recurring-revenue signals, while excess customer inventory and weaker subsequent unit sales were not adequately disclosed. The allegations followed a roughly 18% stock decline and create additional legal, reputational and execution risks, although they have not been proven in court. PROCEPT Discount Program Lawsuit
• Negative Sentiment: Wells Fargo downgraded PRCT from “Overweight” to “Equal Weight” and set a $19 price target, signaling reduced conviction in the shares’ near-term upside.